COL George Peoples, MD, FACS

Closed portfolio with an early-phase archive tilt

According to ClinicalTrials.gov-derived indexes, COL George Peoples, MD, FACS sits in the upper quartile of US sponsors by registered trial count (#2,913 of 15,742 sponsors by registered trial count).

4 total trials none currently recruiting 4 completed early-phase tilt upper quartile by trial count

COL George Peoples, MD, FACS: 4 sponsored US clinical trials, none currently recruiting.

COL George Peoples, MD, FACS sponsors 4 registered US clinical trials on ClinicalTrials.gov, none currently recruiting, and 4 completed. 0 of these trials are in Phase 3-4 (later-stage) and 4 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Breast Cancer, with 1 trials.

Upper-quartile sponsor footprint

COL George Peoples, MD, FACS sits in the upper quartile of the sponsor corpus (#2,913 of 15,742 sponsors by registered trial count) - denser than most sponsors, still short of the top-decile hubs.

How the COL George Peoples, MD, FACS early-phase archive is shaped

4 indexed studies, none listed as recruiting (0% open); 4 completed (100%).

Phase mix: 0 late (III/IV) vs 4 early (I/II) (early-phase heavy).

Top condition: Breast Cancer (1 trial), 0 others listed.

How to read a closed sponsor archive

When recruiting_count is zero, the indexed set is completed or otherwise not open. Phase tilt still describes where archived studies sat on the investigational pathway. Re-check ClinicalTrials.gov before acting.

COL George Peoples, MD, FACS: archived-pipeline peers nationwide

Peers matched on 4 indexed studies with no current recruiting: volume and archive shape, not condition overlap.

COL George Peoples, MD, FACS sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot). 2×2 strategic matrix plotting 9 entities by Total trials (X) and Recruiting share (Y), with a crosshair dividing the plot into four quadrants. Higher volume & more openFocused & more openHigher volume, mostly closedSmaller & mostly closed 051015 0%20%40%60%80% Total trials Recruiting share COL George Peoples, MD, FACS4D pharma60 Degrees PharmaceuticalsA2 BiotherapeuticsAbdul Latif Jameel Poverty Action Lab10xBio22nd Century Group23andMe3-C Institute for Social Development
COL George Peoples, MD, FACS sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot).

COL George Peoples, MD, FACS sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.

Sponsors near 4 archived trials

Sponsors with similar archive density (± trial count)

What to do with this COL George Peoples, MD, FACS page

4 registered trials is a research-attention snapshot, not an endorsement of COL George Peoples, MD, FACS or any single study.

  • None of COL George Peoples, MD, FACS's trials are currently recruiting in this registry; that can change as new trials post, or check the broader research index. Browse research indexes
  • Breast Cancer is the condition COL George Peoples, MD, FACS studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Breast Cancer trials
  • Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. COL George Peoples, MD, FACS pipeline card: 4 registered trials from official public datasets. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.